Novo Nordisk said it recently expanded the services available through its HemaGo mobile application and website, which helps people with hemophilia track their treatment and bleeding episodes.
The new HemaGo XChange allows patients to share that information with their treatment network, a Novo Nordisk release said.
Approximately 20,000 people in the United States have hemophilia, which necessitates ongoing treatment and management. HemaGo helps patients track information that contributes to their care, and using the new HemaGo XChange they can easily share information with their health care team through the web portal or through email.
“Hemophilia is a dynamic condition, impacting many areas of a person’s life,” Novo Nordisk Biopharmaceuticals Marketing Vice President John Spera said in the release. “We developed HemaGo XChange to help drive progress in hemophilia management by turning static data into usable information for people with hemophilia, their care teams and even researchers. With timely information about the daily experiences of patients, including bleeds, health care providers can adjust their care to better fit patient lives.”
Those using the service can also opt to share their tracked data with the American Thrombosis and Hemostasis Network, a national database that collects information on bleeding disorder treatment. To opt-in to sharing their information, patients using HemaGo XChange would make a request via their hemophilia treatment center.